OMER Key Statistics, Chart & Performance
The current stock price of OMER is 9.69 USD. In the past month the price increased by 28.86%. In the past year, price decreased by -14.63%.
OMER Latest News, Press Relases and Analysis
OMER Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.91 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.93 | 498.53B | ||
| MRK | MERCK & CO. INC. | 11.9 | 260.19B | ||
| PFE | PFIZER INC | 8.04 | 146.35B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.5 | 100.14B | ||
| ZTS | ZOETIS INC | 20.22 | 56.49B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.74 | 23.34B | ||
| VTRS | VIATRIS INC | 4.59 | 12.31B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.24 | 11.56B | ||
| CORT | CORCEPT THERAPEUTICS INC | 90.23 | 8.35B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.56B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.80B |
Related stock screener links
About OMER
Company Profile
Omeros Corp. operates as a biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 202 full-time employees. The company went IPO on 2009-10-08. The firm is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Its lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Company Info
OMEROS CORP
201 Elliott Avenue West
Seattle WASHINGTON 98119 US
CEO: Gregory A. Demopulos
Employees: 202
Phone: 12066765000
OMEROS CORP / OMER FAQ
What does OMEROS CORP do?
Omeros Corp. operates as a biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 202 full-time employees. The company went IPO on 2009-10-08. The firm is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Its lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
What is the current price of OMER stock?
The current stock price of OMER is 9.69 USD. The price increased by 0.62% in the last trading session.
Does OMER stock pay dividends?
OMER does not pay a dividend.
What is the ChartMill rating of OMEROS CORP stock?
OMER has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Where is OMEROS CORP (OMER) stock traded?
OMER stock is listed on the Nasdaq exchange.
Can you provide the upcoming earnings date for OMEROS CORP?
OMEROS CORP (OMER) will report earnings on 2026-03-30, after the market close.
OMER Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to OMER. When comparing the yearly performance of all stocks, OMER is one of the better performing stocks in the market, outperforming 94.17% of all stocks.
OMER Financial Highlights
Over the last trailing twelve months OMER reported a non-GAAP Earnings per Share(EPS) of -2.02. The EPS increased by 12.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -65.24% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
OMER Forecast & Estimates
11 analysts have analysed OMER and the average price target is 34.34 USD. This implies a price increase of 254.39% is expected in the next year compared to the current price of 9.69.